One Medication or Many? Navigating Psychiatric Monotherapy vs. Polypharmacy

Psychiatric medication decisions rarely follow a simple algorithm. The choice between monotherapy (one medication) and polypharmacy (multiple medications) hinges on diagnosis, severity, treatment history, side effect profile, and patient values. There's no universal "better"—only what's better for this person, right now.

When Monotherapy Makes Sense

  • Mild to moderate illness responding well to a single agent at therapeutic dose.
  • First-time treatment: Starting simple establishes a clear baseline for efficacy and side effects.
  • Minimizing complexity: Fewer drug interactions, simpler adherence, lower cumulative side-effect burden.
  • Patient preference: Some prioritize simplicity and "less medicine in my body."

When Polypharmacy Is Justified

1. Complex or Treatment-Resistant Conditions

  • Bipolar disorder with mixed features often requires mood stabilizer + antipsychotic + adjunctive antidepressant.
  • Schizophrenia with prominent negative symptoms may need antipsychotic + antidepressant + cognitive enhancer.
  • Treatment-resistant depression (failed ≥2 adequate monotherapy trials) often responds to augmentation (e.g., adding aripiprazole, liothyronine, or ketamine/esketamine).

2. Targeting Distinct Symptom Clusters

  • Antidepressant for mood + antipsychotic for psychotic features.
  • Stimulant for ADHD + alpha-agonist for emotional dysregulation.
  • Mood stabilizer + benzodiazepine (short-term) for acute agitation.

3. Managing Side Effects Strategically

  • Adding bupropion to counteract SSRI-induced sexual dysfunction.
  • Adding metformin for antipsychotic-associated weight gain/metabolic effects.
  • Using propranolol for akathisia or performance anxiety.

Key Decision Factors

  1. Treatment resistance: Has an adequate monotherapy trial (right drug, right dose, right duration) failed?
  2. Side-effect tolerance: Is the limiting factor efficacy or tolerability? Switching may beat adding.
  3. Long-term trajectory: Maintenance often requires different strategies than acute stabilization.
  4. Drug interaction profile: CYP450 interactions, QT prolongation, serotonergic load, anticholinergic burden.
  5. Patient values: Some accept complexity for symptom control; others prioritize minimalism.

The Collaborative Process

This isn't a decision the psychiatrist makes for the patient—it's a shared deliberation:

  • Review evidence for each option, including number needed to treat (NNT) and number needed to harm (NNH).
  • Define clear targets: "What specific symptoms should improve? In what timeframe?"
  • Set monitoring checkpoints: rating scales, labs, weight, metabolic panels.
  • Establish an exit strategy: "If we add this, when and how do we reassess? Can we taper later?"

Red Flags for Unnecessary Polypharmacy

  • Multiple medications from the same class (e.g., two SSRIs, two antipsychotics) without clear rationale.
  • Prescribing cascades: Drug A causes side effect → Drug B treats it → Drug B causes new side effect → Drug C...
  • No documented trial of monotherapy optimization before adding.
  • Patient unclear on why each medication exists.

The goal isn't fewer pills—it's the right regimen. Sometimes that's one. Sometimes it's three. The art is knowing the difference, monitoring rigorously, and never losing sight of the person behind the prescription.

Mental Health (General) - Related Articles